Cover Image

Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies

Abstract Ivosidenib is a once daily (q.d.), orally available, potent mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor approved for treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and intensive chemotherapy ineligible AML with a susceptible IDH1 mutation. Popul...

Full description

Saved in:
Bibliographic Details
Main Authors: Xuemin Jiang (Author), Russ Wada (Author), Bill Poland (Author), Huub Jan Kleijn (Author), Bin Fan (Author), Guowen Liu (Author), Hua Liu (Author), Stephanie Kapsalis (Author), Hua Yang (Author), Kha Le (Author)
Format: Book
Published: Wiley, 2021-05-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items